


Amendments to the Claims:


1. (Original) A compound of the formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

A and B independently represent CH₂ or O, with the proviso that A and B are not simultaneously O;

Cy represents one of the following



optionally substituted by one to three groups selected from hydroxy, halogen, C₁₋₆alkyl,

C₁₋₆alkoxy, C₁₋₆haloalkyl, C₁₋₆alkylamino and amino;

R¹ and R² are independently selected from hydroxy, halogen, C₁₋₆alkyl, C₁₋₆alkoxy,

C₁₋₆haloalkyl and C₃₋₈ cycloalkyl;

n represents an integer from 0-4;

X is hydrogen, hydroxy, halogen or C₁₋₆ alkoxy;

Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen, C₁₋₆alkyl, C₁₋₆alkoxy and C₁₋₆haloalkyl;

Z is CH or N; and

p represents an integer from 0-5 when Z is CH or 0-4 when Z is N,

when p represents 2 or more, two of R²'s may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring.

2. (Currently Amended) A compound according to claim 1 where wherein A and B represent carbon atoms.

3. (Currently Amended) A compound according to claim 1 where wherein A represents O and B represents C.

4. (Currently Amended) A compound according to claim 1 where wherein A represents C and B represents O.

5. (Currently Amended) A compound according to any one of claims 1-to-4 where Cy is selected from optionally further substituted 4-hydroxyphenyl, 1*H*-pyrazol-4-yl, 2-oxo-2,3-dihydro-1,3-benzoxazole-6-yl and 2-hydroxy-5-pyridyl.

6. (Currently Amended) A compound according to any one of claims 1 to 5 where wherein Cy represents 4-hydroxyphenyl, optionally further substituted by fluoro or methyl.

7. (Currently Amended) A compound according to any one of claims 1 to 6 where wherein n represents 0.

8. (Currently Amended) A compound according to any one of claims 1 to 7 wherein
R² represents methoxy, chloro, fluoro or methyl.

9. (Currently Amended) A compound according to any one of claims 1 to 8 wherein
p represents 0-2.

10. (Currently Amended) A compound according to any one of claims 1 to 9 wherein
X is hydrogen or hydroxy.

11. (Currently Amended) A compound according to any one of claims 1 to 10
wherein Y is selected from methylene, oxyethyleneoxy, oxymethylene, methyleneoxy,
methyleneoxymethylene, ethyleneoxy, oxyethylene and oxy.

12. (Currently Amended) A compound according to any one of claims 1 to 11
wherein Y is para located to and in a *trans* configuration to X.

13. (Currently Amended) A compound of formula (I) selected from the group consisting of:
4-Hydroxy-N-[(*cis*-4-(phenoxy)methyl)cyclohexyl]methyl)benzamide;
4-Hydroxy-N-((*cis*-4-[(4-methoxyphenoxy)methyl]cyclohexyl)methyl)benzamide;
N-[(*cis*-4-(Benzoyloxy)cyclohexyl)methyl]-4-hydroxybenzamide;
N-((*cis*-4-[(4-Chlorobenzyl)oxy]cyclohexyl)methyl)-4-hydroxybenzamide;
N-((*cis*-4-[(3-Chlorobenzyl)oxy]cyclohexyl)methyl)-4-hydroxybenzamide;
4-Hydroxy-N-[(*cis*-4-(4-methoxyphenoxy)cyclohexyl)methyl]benzamide;
N-[(*cis*-4-(4-Chlorophenoxy)cyclohexyl)methyl]-4-hydroxybenzamide;
4-Hydroxy-N-[(1-hydroxy-4-(phenoxy)methyl)cyclohexyl]methyl)benzamide;
N-((*trans*-4-[(4-Fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl)-4-hydroxybenzamide;
N-((*trans*-4-[(3-Fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl)-4-hydroxybenzamide;
N-((*trans*-4-[(2-Fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl)-4-hydroxybenzamide;
N-((*trans*-4-[(2,6-Difluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl)-4-hydroxybenzamide;
N-((*trans*-4-[(3,5-Difluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl)-4-hydroxybenzamide;
N-((*trans*-4-[(3-Chlorophenoxy)methyl]-1-hydroxycyclohexyl)methyl)-4-hydroxybenzamide;
N-((*trans*-4-[(4-Chlorophenoxy)methyl]-1-hydroxycyclohexyl)methyl)-4-hydroxybenzamide;
4-Hydroxy-N-((*trans*-1-hydroxy-4-[(2-methylphenoxy)methyl]cyclohexyl)methyl)benzamide;

4-Hydroxy-N-({*trans*-1-hydroxy-4-[(3-methylphenoxy)methyl]cyclohexyl}methyl)benzamide;
4-Hydroxy-N-({*trans*-1-hydroxy-4-[(4-methylphenoxy)methyl]cyclohexyl}methyl)benzamide;
N-({*trans*-4-[(Benzyoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-[(*trans*-4-[(2-Fluorobenzyl)oxy]methyl]-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
N-[(*trans*-4-[(4-Fluorobenzyl)oxy]methyl]-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
4-Hydroxy-N-[(*trans*-1-hydroxy-4-(2-phenoxyethyl)cyclohexyl)methyl]benzamide;
N-({*trans*-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[2-(3-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[2-(4-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-[(*trans*-4-(Benzyoxy)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
N-[(*trans*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
N-[(*cis*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
N-[(*trans*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl)methyl]-3-fluoro-4-hydroxybenzamide;
N-[(*cis*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl)methyl]-3-fluoro-4-hydroxybenzamide;
(+)-4-hydroxy-N-[(5*S*-(phenoxy)methyl)tetrahydro-2*H*-pyran-2*S*-yl]methyl]benzamide;
(-)-4-hydroxy-N-[(5*R*-(phenoxy)methyl)tetrahydro-2*H*-pyran-2*R*-yl]methyl]benzamide;
4-hydroxy-N-[(5*S*-(benzyloxy)methyl)tetrahydro-2*H*-pyran-2*S*-yl]methyl]benzamide;
4-hydroxy-N-[(5*R*-(benzyloxy)methyl)tetrahydro-2*H*-pyran-2*R*-yl]methyl]benzamide;
(-)-4-Hydroxy-N-[(3*R*,6*S*)-6-(phenoxy)methyl)tetrahydro-2*H*-pyran-3-yl]methyl]benzamide;
(+)-4-Hydroxy-N-[(3*S*,6*R*)-6-(phenoxy)methyl)tetrahydro-2*H*-pyran-3-yl]methyl]benzamide;
N-({*trans*-4-[(2-Fluorobenzyl)oxy]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
3-Fluoro-N-({*trans*-4-[2-(2-fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
trans- N-[(4-(4-chlorophenoxy)cyclohexyl)methyl]-3-fluoro-4-hydroxybenzamide;
cis- N-[(4-(4-chlorophenoxy)cyclohexyl)methyl]-3-fluoro-4-hydroxybenzamide;
N-[(*cis*-4-(4-Fluorophenoxy)cyclohexyl)methyl]-4-hydroxybenzamide;
3-Fluoro-N-[(*cis*-4-(4-fluorophenoxy)cyclohexyl)methyl]-4-hydroxybenzamide;
N-({*trans*-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-1*H*-pyrazole-4-carboxamide;
4-hydroxy-N-[(*cis*-4-(2-phenylethoxy)cyclohexyl)methyl]benzamide;
2-fluoro-4-hydroxy-N-[(*trans*-1-hydroxy-4-(phenoxy)methyl)cyclohexyl]methyl]benzamide;
N-({*trans*-4-[(benzyloxy)methyl]-1-hydroxycyclohexyl}methyl)-3-fluoro-4-hydroxybenzamide;
N-[(*cis*-4-[(Benzyoxy)methyl]cyclohexyl)methyl]-4-hydroxybenzamide

3-Fluoro-4-hydroxy-N-[[*trans*-1-hydroxy-4-(phenoxyethyl)cyclohexyl]methyl]benzamide;
3-Fluoro-4-hydroxy-N-[[*trans*-1-hydroxy-4-(2-phenoxyethyl)cyclohexyl]methyl]benzamide;
3-Fluoro-N-[(*trans*-4-[(4-fluorobenzyl)oxy]methyl)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
3-Fluoro-N-[(*trans*-4-[(2-fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
3-Fluoro-N-[(*trans*-4-[(4-fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
4-Hydroxy-N-[(*trans*-1-hydroxy-4-[(5-methylpyridin-2-yl)oxy]methyl)cyclohexyl)methyl]benzamide;
N-[(*trans*-4-Benzyl-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
3-fluoro-N-[(*trans*-4-[(2-fluorobenzyl)oxy]methyl)-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
6-Hydroxy-N-[[*cis*-4-(2-phenethoxy)cyclohexyl]methyl]nicotinamide;
N-[(*cis*-4-(2-Phenylethoxy)cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-[(*cis*-4-(Phenoxyethyl)cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-[(*cis*-4-(2-Phenoxyethyl)cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-[(*cis*-4-[(3-Fluorophenoxy)methyl]cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-[(*cis*-4-[(4-Fluorophenoxy)methyl]cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-((2*R*,5*R*)-5-[(4-Fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide;
N-[(*cis*-4-(4-Methoxybenzyl)cyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
3-Amino-N-[(*cis*-4-benzylcyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-((2*R*,5*R*)-5-[(4-Chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide;
3-Amino-N-((2*R*,5*R*)-5-[(4-fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide;
3-Amino-N-((2*R*,5*R*)-5-[(4-chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide; and
3-Amino-N-((2*R*,5*R*)-5-[(4-ethylphenoxy)methyl]tetrahydro-2*H*-pyran-2-yl)methyl]-1*H*-pyrazole-4-carboxamide;
or a pharmaceutically acceptable salt or solvate thereof.

14. (Currently Amended) A pharmaceutical composition including a compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1 to 13, together with a pharmaceutically acceptable excipient.

15. (Currently Amended) A compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1 to 14, for use as a medicament.

16. (Cancel)

17. (Cancel)

18. (Currently Amended) A method of treatment of a mammal, including a human being, to treat a disease for which an NMDA NR2B antagonist is indicated, including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof, as defined in any one of claims 1 to 13 and 14, respectively.

19. (Currently Amended) A method according to claim 18 wherein the disease is selected from pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety and migraine.

20. (Currently Amended) A combination of a compound of the formula (I), as defined in any one of claims 1 to 13, and another pharmacologically active agent.